SCHEMBL19465037

SCHEMBL19465037

CNC(=O)C(=O)c1cc(OC)c(OC)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.54
▸ HPGD P15428 1/20 0.54
▸ TUBB1 Q9H4B7 7/20 0.51
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.49
▸ TUBB4A P04350 3/20 0.49
▸ TUBB P07437 3/20 0.49
▸ TUBA3C P0DPH7 3/20 0.49
▸ TUBA1B P68363 3/20 0.49
▸ TUBA4A P68366 3/20 0.49
▸ TUBB4B P68371 3/20 0.49
▸ TUBB3 Q13509 3/20 0.49
▸ TUBB2A Q13885 3/20 0.49
▸ TUBB8 Q3ZCM7 3/20 0.49
▸ TUBA3E Q6PEY2 3/20 0.49
▸ TUBA1A Q71U36 3/20 0.49
▸ TUBA1C Q9BQE3 3/20 0.49
▸ TUBB6 Q9BUF5 3/20 0.49
▸ TUBB2B Q9BVA1 3/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4625442 0.84 TUBB1 (0.58) ALDH1A1TUBB1MEN1KMT2AKDM4E
SCHEMBL8590728 0.82 ALDH1A1 (0.51) ALDH1A1HPGDTUBB1MEN1KMT2A
SCHEMBL4143482 0.81 ALDH1A1 (0.77) ALDH1A1HPGDMEN1KMT2AMAPK1
SCHEMBL31679677 0.81 TUBB1 (0.54) ALDH1A1HPGDTUBB1MEN1KMT2A
SCHEMBL20079471 0.81 ALDH1A1 (0.60) ALDH1A1TUBB1MEN1KMT2AKDM4E
SCHEMBL23734449 0.79 TUBB1 (0.55) ALDH1A1TUBB1MEN1KMT2AKDM4E
SCHEMBL907576 0.79 TPMT (0.56) ALDH1A1HPGDTUBB1MEN1KMT2A
SCHEMBL23734331 0.78 TUBB1 (0.49) ALDH1A1HPGDTUBB1MEN1KMT2A
SCHEMBL6160353 0.77 TUBB1 (0.54) ALDH1A1HPGDTUBB1MEN1KMT2A
SCHEMBL10789120 0.77 TSHR (0.56) TUBB1MEN1KMT2ATUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790197-B2 Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient KATHOLIEKE UNIVERSITEIT LEUVEN K.U. LEUVEN R & D (BE) 2017-10-17 — — US disclosed
Send feedback